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Abstract 
 
Arecoline, the main alcaloid of Areca cathecu L has been proven to posses cytotoxic 
activity against various cancer cell lines. The research conducted to examine the cytotoxic 
activity of arecoline alone and its combination with doxorubicin against HeLa cervical cancer 
cell line. Single treatment of arecoline in various concentration on HeLa cancer cell were 
done followed by the combinational treatment with doxorubicin. The cell viability as the 
parameter of cytotoxicity was measured using MTT (3-(4,5-dimetiltiazol-2-il)-2,5-
difeniltetrazolium bromide) assay. The apoptotic effect was examined by double staining 
assay using etidium bromide-acridin orange.  Arecoline did not show potent cytotoxicity 
effect against HeLa since the value of IC50 is 462 µM. The combinational treatment of 
arecoline and doxorubicin showed synergicity with the optimum CI value is 0.48 given by the 
treatment of 30mM arecoline combined with 125 nM doxorubicin. The result of this study 
shows that arecoline has potential to be proposed as co-chemotherapeutic agent for cervical 
cancer. However, further study on its molecular mechanism needs to be conducted.   
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INTRODUCTION 
 
Cervical cancer is the second most 
common cancer found in women all over the 
world. International Agency for Research in 
Cancer reported that in 2008 there are 532.232 
cases of cervical cancer in 100 million women. 
One of chemotherapeutic agents that commonly 
used is doxorubicin. Unfortunately, a recent 
study showed that high dose of doxorubicin 
may cause cardiotoxicity in human (Gunawan, 
2007). It is possible to lower the dose of 
doxorubicin for therapy but it will also lessen 
the activity (Wattanapitayakul, et al., 2005). 
Therefore, it is needed to develop a new 
approach of treatment such as using co-
chemotherapeutic agents. 
Arecoline (C8H13NO2) is an alkaloid 
compound found in pinang fruit (Areca catechu 
L.). Some in vitro study showed that arecolin 
have cytotoxicity towards oral and liver cancer 
cells, and induce apoptosis in basal cancer cells 
(Chang, et al., 2001; Cheng, et al., 2010). 
Arecoline is a promising compound to be used 
as co-chemotherapeutic agent of doxorubicin. 
Previous study showed that arecoline is able to 
induce cell cycle arrest in KB cell line (Chang, 
et al., 2001). It is recently reported by Cheng, et 
al in 2010 that arecoline may induce apotosis in 
human hepatoma HA22T/VGH cell line 
through the by supressing the production of 
Bcl-XL and Bcl-2 protein, increasing p53 
production, and inducing the release of 
cytochrom c from mitochondrial membrane. 
HeLa cells are known to express 2 
kinds of oncogenes, E6 and E7. E6 bounds with 
p53 fosforilated protein meanwhile the E7 
bounds with pRb protein (Jansen, et al., 2006). 
The bonding of p53 protein by the E6 causing 
the increase of protein's degradation rate. 
Arecoline reported to have ability in increasing 
the p53 expression and the expression of the 
gen that encode the p21
WAF1 
(Chou, et al., 
2009). Besides, the arecoline can alo induce the 
expression of Bax, the proapoptotic protein and 
inhibits the Bcl-2 which is antiapoptosis protein 
on hepatoma cells HA22T/VGH (Cheng, et al., 
2010). 
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MATERIALS AND METHODS 
 
Tested Compounds 
The main compounds used in this study 
was Arecoline Hydrobromide (VETRANAL
® 
Sigma Aldrich Number of Catalog 46063) 
obtained from Warista Yogyakarta. The 
chemotherapy  agent  doxorubicin  in  the  form 
of injection solution in the concentration of 50 
mg/25 mL (Kalbe Farma) were obtained from 
Dr. Sardjito Hospital Yogyakarta. 
 
Cell Culture 
HeLa cells were the collection of Cancer 
Chemoprevention Research Center, Faculty of 
Pharmacy, Universitas Gadjah Mada. Cells 
were cultured in the DMEM culture media 1640 
(Gibco) containing 10 % v/v Fetal Bovine 
Serum (FBS) (Gibco) and penisillin-
streptomycin 100 μg/mL (Gibco) and incubated 
in CO2 incubator (Herceus) in the 37C 
themperature and 5% CO2. 
 
Cytotoxic Assay  
The cytotoxicity assay were done by 
MTT assay. HeLa cells were distributed in to 
96 well plates (Nunc) with 5000 in cells each 
well. The cells were incubated for 24 hours in 
the CO2 incubator (Herceus) with arecolin both 
for the single and combinational cytotoxic 
assay. DMSO was used as the solvent. In the 
end of the incubation time, each well were 
added by 100 µL MTT reagent (Sigma) in the 
DMEM culture media (Gibco). The plate were 
incubated for 4 hours in 37
o
C themperature 
until the formazan crystal were formed (to 
observed the formazan crystal were done under 
the inverted microscope (Olympus CH-2)). 
After 4 hours of incubation  the reaction were 
stopped by adding the SDS 10% as stopper 
reagent as many as 100 µL in each well and 
was incubated for 24 hours  in the room 
themperature.  
This proccess provide the color change 
in the cells' media. The yellow colour would 
turn into purple because of the dehidrogenase 
enzim activity in the living cells which breaks 
the tetrazolium rings from MTT reagents in to 
formazan crystal. The intensity if absorbance of 
the formazan crystal were obtained by the 
ELISA reader Bio-Rad microplate reader 
Benchmark serial no. 11565, Japan) with 595 
nm wavelenght. 
 
 
Apoptosis Induction 
The confluent culture of HeLa cells wre 
harvested and distributed in the concentration 
of 5 x 10
4
 cells/well on the coverslips (Nunc) 
and added by 1000 μL of culture media. Cells 
were incubated for 24 hours in the CO2 
incubator so that cells were adapted and in 
normal condition. Cells were given the 
treatment as control cells,    ⁄  IC50 arecoline, 
 
 ⁄  IC50 arecoline, 
 
 ⁄  IC50 doxorubicin, 
combination of    ⁄  IC50 arecoline with 
 
 ⁄  IC50 
doxorubicin, and combination of    ⁄  IC50 
arecoline with   ⁄  IC50 doxorubicin, and then 
incubated for 24 hours. In the end of 
incubation, the DMEM culture media were 
washed by PBS and the cover slips were lifted 
and placed on the object glass and were 
dropped by etidium bromide-acridine orange as 
many as 10 μL. The observation of cells 
morphology were done under the fluorescence 
microscope (Zeiss MC 80). 
 
Data Analysis 
Cytotoxicity Assay 
The absorbation of each well were 
converted in to the percent of cell viability. The 
percent of cell viability were calculated by the 
formula:  
 
                 
                          
              
      
 
Based on the regretion equation were 
counted the IC50 concentration (the 
concentration causing death fo 50% of 
population) so that can be determined the 
cytotoxic potency (Doyle and Griffiths, 2000). 
 
Combinational Cytotoxicity Assay. 
Combinational treatment was evaluated 
by calculating Combination Index (CI) value 
(Reynolds and Maurer, 2005), which has the 
formula as follows: 
 
CI = D1/Dx1 + D2/Dx2 
 
D1 and D2 represent concentrations used 
in combinational treatment, while Dx1 and Dx2 
are single treatment concentration giving same 
response as D1 and D2, respectively. CI value 
acquired will allow the evaluation of 
Arecoline’s potency in combinatorial treatment 
with doxorubicin on HeLa cells. Interpretation 
was done based on the classification listed in 
Table 1. 
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Table 1. Interpretation of CI value representing potency of combinational application 
CI Interpretation CI Interpretation 
< 0.1 Very strong synergist 0.9-1.1 Closely additive 
0.1-0.3 Strongly synergist 1.1-1.45 Middle antagonist 
0.3-0.7 Synergist 1.45-3.3 Antagonist 
0.7-0.9 Middle synergist >3.3 Strongly antagonist 
  
 
Apoptosis Assay Analysis 
The green fluorescence showed the 
living cells. The early stage of apoptosis will 
undergo the chromatin condensation and will be 
green in colour. Meanwhile the late apoptotsis 
cells will be broken in to the small parts and 
become orange in colour (Renvoize, et al., 
1998). 
 
RESULTS AND DISCUSSION 
 
Effect of Arecoline on HeLa Cells 
Growth 
The cytotoxic assay was done to 
determine the cytotoxic potency of Arecoline as 
tested compound. The potency was expressed in 
the parameter of IC50. The treatment of 
arecoline in the concentration of 1 µM, 10 µM, 
50 µM, 100 µM, 250 µM, 500 µM, 750 µM, 
and 1000 µM on HeLa cells caused HeLa cells 
growth decreased as the concentration of 
compound increased. Based on this study, the 
IC50 of Arecoline on HeLa cells is 462 µg/mL 
(Fig. 1). The observation of HeLa cells 
morphology after the treatment of arecoline 
showed the cells death (cells become round in 
shape and deattached from the well plate) 
increased as the concentration of arecolin 
increased (Fig. 2)  
This IC50 value of arecoline on HeLa 
cells showed that arecoline do not cause the 
strong cytotoxic activity on HeLa cells, 
compared with the other alkaloid such as 
scimmiamianin, flindercin, and haplopine 
(Jansen, et al., 2006). Although the cytotoxic 
effect of this compound is not too strong, it is 
still possible for arecoline to be used as co-
chemotherapy agent with doxorubicin. 
Doxorubicin is known to have IC50 value 
1000 nM on HeLa cells (Larasati, 2010). This 
showed that HeLa cells is not too sensitive with 
the treatment of doxorubicin. The IC50 value on 
HeLa cells is higher than the IC50 value of 
doxorubicin in other cancer cell such as T47D 
(43 nM) (Larasati, 2010; Jenie and Meiyanto, 
2006). This could be caused by the resistence of 
doxorubicin on HeLa cells by the antiapoptotic 
protein in HeLa cells, ARC (apoptosis 
repressor with caspase recruitment domain) 
and efflux mechanism of doxorubicin from 
HeLa cells (Wang, et al., 2009, Bravo-Cuellar, 
et al., 2010). Therefore, the observation of 
combinational cytotoxicity of these two 
compound is needed to be done. 
 
 
Figure 1. The effect arecoline on the growth of HeLa cells. As many as 5000 cells/well HeLa cells were 
incubated in the 96 well plates, and given the treatment of arecoline in the range concentration 1-1000 
µM.  
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Figure 2.   The effects of single treatment of arecoline on the HeLa cells morphology. As many as 5000 
cells/well were incubated in the 96 well plates. The observation of cell's morphology were done by 
using inverted microscope with 100x magnification. The figure showed control cells (A), cells treated 
by arecoline 1 µM (B), 10 µM (C), 50 µM (D), 100 µM (E), 250 µM (F), 500 µM (G) ,750 µM (H), and 
1000 µM (I). The arrow  showed viable cells, meanwhile        showed death cells. 
 
  
Effect of Arecoline Combined with 
Doxorubicin on HeLa Cells Growth 
Combination assay was done by 
combining    ⁄  IC50, 
 
 ⁄  IC50, 
 
 ⁄  IC50 
 
 ⁄  IC50 
of Arecoline with    ⁄  IC50, 
 
 ⁄  IC50, 
 
 ⁄  
IC50   ⁄  IC50 of doxorubicin. The cells viability 
were quantified by combination index (CI). 
Table II showed that the optimum IC value 
were obtained by combining    ⁄  IC50 arecoline 
with   ⁄  IC50 doxorubicin with IC value 0.48, 
and the combination of   ⁄  IC50 arecoline with 
 
 ⁄  IC50 doxorubicin with CI value 0.52. The 
synergistic effect of doxorubicin in the 
combination with Arecoline probably through 
the apoptosis induction mechanism so taht the 
observation of this mechanism should be done. 
 
 
 
Table 2. Combination Index combination of CEO and doxorubicin 
Arecoline (µg) Doxorubicin (nM) 
62.5 125 250 375 
30 0.76 0.48 0.72 0.88 
60 0.79 0.84 1.17 1.83 
120 0.62 0.81 1.72 1.77 
175 0.56 0.52 1.06 1.39 
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Treatment with combination of CEO 
37.5 µg/mL and doxorubicin 1.25 µM reduced 
cell viability significantly different with single 
treatment of each agent. While combination 
treatment with lower concentration of CEO 
(9.375 µg/mL) and doxorubicin did not reduce 
cell viability significantly compound to the 
doxorubicin solely (Fig. 2). 
 
Effect of CEO and Doxorubicin on 
Apoptosis Induction 
Double staining using ethidium bromide 
and acridin orange was used to observe the 
induction of apoptosis.  Single treatment of 
CEO 37.5 µg/mL and doxorubicin 5 µM 
induced apoptosis of T47D cells. Apoptotic 
induction was indicated by orange fluorescent 
in the nucleus (Fig. 3). The result showed that 
combination treatment of CEO and doxorubin 
increased the number of cells containing 
red/orange fluorescent. These data indicated 
that the combination of CEO and doxorubicin 
increased the incidence of apoptosis. 
The therapy of cervical cancer by 
doxorubicin needs high dose of treatment and 
usually cause the side effects such as nausea, 
hair loss, and cardiotoxicity. The synergistic 
effect of arecolin in the combination with 
doxorubicin can reduce the dose of doxorubicin 
to obtain the same effect. As the dose is 
reduced, the side effect of doxorubicin can be 
reduced. Doxorubicin can induce the DNA 
strand break so that induce apoptosis. 
(Drummond, 2007). Arecoline also reported to 
induce the DNA strand break in mamalia cells 
(Chang, et al., 2001). The synergistic effect of 
these two compounds are probably by the DNA 
strand break mechanism. 
 
The effect of arecoline and combination 
with doxorubicin in the apoptosis 
induction  
The determination of the induction of 
apoptosis by the combination of Arecoline with 
doxorubicin in HeLa cells were done by 
apoptosis assay by double staining method. The 
result of this assay showed that the combination 
of arecoline and doxorubicin can induce the 
better apoptosis incidence than the single 
treatment of each compound. The apoptosis 
effect showed by the fluorescence of tge cells in 
to orang ecolour that caused by the decrease of 
membrane cells permeability. Some cells 
showed the nucleus fragmentation and the 
formation of apoptotic body (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  The effects of combination treatment of arecoline with doxorubicin on the HeLa cells 
viability. Cells were incubated for 24 hours and given the treatment of arecoline in combination with 
doxorubicin    ⁄ IC50, 
 
 ⁄  IC50, 
 
 ⁄ IC50     
 
 ⁄  IC50. The graph shows HeLa cells viability after the 
treatment (p<0.05).  
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Figure 4.  The effects of single and combination of arecoline and doxorubicin in the induction of 
apoptosis on HeLa cells. Control cells (A),  Doxorubicin 125 nM (B), Arecoline 175 μM (C), and 
the combination of 175 μM arecoline and  125 nM doxorubicin. The yellow arrows           show the 
viable cells which green in fluorescence, and the red arrows            show the death cells which orange 
in fluorescence.  
 
The induction of apoptosis by arecoline 
on HeLa cells probably by the p53 dependent 
mechanism and physical mechanism such as 
anoikis. This study showed the cytotoxic 
activity of arecoline and the synergistic effect 
of arecoline in the combination with 
doxorubicin on HeLa cells. The further research 
is need to be done to explain the molecular 
mechanism that mediate the cytotoxic activity 
of arecoline on HeLa cells and the synergistic 
effect with doxorubicin. 
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